ADC Therapeutics SANYSE:ADCT
- LAST PRICE1.9550
- TODAY'S CHANGE (%)0.0150 (0.7732%)
- Bid / Lots1.9500/ 8
- Ask / Lots1.9600/ 8
- Open / Previous Close1.9200 / 1.9400
- Day Range
- 52 Week Range
- Volume365,840
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ADCT |
|---|---|---|
| 09:32 ET | 8383 | 1.95 |
| 09:33 ET | 1000 | 1.91 |
| 09:35 ET | 2035 | 1.91 |
| 09:37 ET | 12648 | 1.9198 |
| 09:39 ET | 1142 | 1.915 |
| 09:42 ET | 2801 | 1.91 |
| 09:44 ET | 17166 | 1.87 |
| 09:46 ET | 5564 | 1.89 |
| 09:48 ET | 300 | 1.89 |
| 09:50 ET | 811 | 1.9 |
| 09:51 ET | 600 | 1.89 |
| 09:53 ET | 502 | 1.8899 |
| 09:55 ET | 10913 | 1.885 |
| 09:57 ET | 16244 | 1.87 |
| 10:00 ET | 10741 | 1.905 |
| 10:02 ET | 1389 | 1.91 |
| 10:04 ET | 4980 | 1.915 |
| 10:06 ET | 1816 | 1.92 |
| 10:08 ET | 1721 | 1.91 |
| 10:09 ET | 3164 | 1.91 |
| 10:11 ET | 2563 | 1.92 |
| 10:13 ET | 6330 | 1.92 |
| 10:15 ET | 4199 | 1.92 |
| 10:18 ET | 1610 | 1.93 |
| 10:20 ET | 1221 | 1.95 |
| 10:22 ET | 430 | 1.955 |
| 10:24 ET | 19363 | 1.955 |
| 10:26 ET | 1100 | 1.96 |
| 10:27 ET | 1069 | 1.95 |
| 10:29 ET | 2185 | 1.94 |
| 10:31 ET | 1108 | 1.94 |
| 10:33 ET | 1665 | 1.93 |
| 10:36 ET | 1464 | 1.94 |
| 10:38 ET | 873 | 1.955 |
| 10:40 ET | 7015 | 1.95 |
| 10:42 ET | 12701 | 1.935 |
| 10:44 ET | 2348 | 1.93 |
| 10:45 ET | 400 | 1.93 |
| 10:47 ET | 500 | 1.93 |
| 10:49 ET | 1249 | 1.93 |
| 10:51 ET | 1218 | 1.91 |
| 10:54 ET | 1120 | 1.91 |
| 10:56 ET | 6343 | 1.91 |
| 10:58 ET | 1281 | 1.92 |
| 11:00 ET | 801 | 1.93 |
| 11:02 ET | 640 | 1.93 |
| 11:03 ET | 3900 | 1.91 |
| 11:05 ET | 1194 | 1.92 |
| 11:07 ET | 900 | 1.925 |
| 11:09 ET | 6447 | 1.935 |
| 11:12 ET | 100 | 1.935 |
| 11:14 ET | 1000 | 1.945 |
| 11:16 ET | 390 | 1.94 |
| 11:18 ET | 11243 | 1.935 |
| 11:20 ET | 477 | 1.94 |
| 11:21 ET | 572 | 1.95 |
| 11:23 ET | 600 | 1.955 |
| 11:25 ET | 600 | 1.955 |
| 11:27 ET | 700 | 1.955 |
| 11:30 ET | 6809 | 1.97 |
| 11:32 ET | 2799 | 1.95 |
| 11:34 ET | 500 | 1.95 |
| 11:36 ET | 300 | 1.95 |
| 11:38 ET | 500 | 1.95 |
| 11:39 ET | 300 | 1.95 |
| 11:41 ET | 500 | 1.95 |
| 11:43 ET | 400 | 1.95 |
| 11:45 ET | 1972 | 1.965 |
| 11:48 ET | 1299 | 1.965 |
| 11:50 ET | 524 | 1.96 |
| 11:52 ET | 200 | 1.96 |
| 11:54 ET | 400 | 1.96 |
| 11:56 ET | 400 | 1.965 |
| 11:57 ET | 100 | 1.96 |
| 11:59 ET | 750 | 1.97 |
| 12:01 ET | 691 | 1.965 |
| 12:03 ET | 1012 | 1.975 |
| 12:06 ET | 5395 | 1.985 |
| 12:08 ET | 100 | 1.985 |
| 12:10 ET | 300 | 1.98 |
| 12:12 ET | 544 | 1.98 |
| 12:14 ET | 300 | 1.97 |
| 12:15 ET | 900 | 1.965 |
| 12:17 ET | 375 | 1.975 |
| 12:19 ET | 300 | 1.97 |
| 12:24 ET | 300 | 1.97 |
| 12:26 ET | 300 | 1.9701 |
| 12:30 ET | 200 | 1.97 |
| 12:32 ET | 330 | 1.97 |
| 12:33 ET | 200 | 1.965 |
| 12:35 ET | 400 | 1.96 |
| 12:37 ET | 4546 | 1.985 |
| 12:42 ET | 3024 | 1.99 |
| 12:44 ET | 1100 | 1.985 |
| 12:46 ET | 300 | 1.985 |
| 12:48 ET | 200 | 1.98 |
| 12:50 ET | 4119 | 1.99 |
| 12:51 ET | 2700 | 1.99 |
| 12:53 ET | 300 | 1.98 |
| 12:55 ET | 200 | 1.98 |
| 12:57 ET | 200 | 1.98 |
| 01:00 ET | 300 | 1.98 |
| 01:02 ET | 200 | 1.98 |
| 01:04 ET | 3198 | 1.975 |
| 01:06 ET | 1584 | 1.9817 |
| 01:08 ET | 100 | 1.985 |
| 01:09 ET | 100 | 1.985 |
| 01:11 ET | 400 | 1.985 |
| 01:13 ET | 200 | 1.98 |
| 01:15 ET | 206 | 1.98 |
| 01:18 ET | 200 | 1.985 |
| 01:20 ET | 300 | 1.985 |
| 01:22 ET | 500 | 1.99 |
| 01:26 ET | 9339 | 1.99 |
| 01:27 ET | 100 | 1.99 |
| 01:31 ET | 100 | 1.985 |
| 01:33 ET | 2261 | 1.97 |
| 01:36 ET | 5633 | 1.97 |
| 01:38 ET | 2363 | 1.98 |
| 01:40 ET | 2232 | 1.975 |
| 01:42 ET | 1196 | 1.97 |
| 01:44 ET | 100 | 1.97 |
| 01:45 ET | 100 | 1.97 |
| 01:47 ET | 200 | 1.965 |
| 01:49 ET | 1991 | 1.95 |
| 01:51 ET | 300 | 1.955 |
| 01:54 ET | 600 | 1.955 |
| 01:56 ET | 500 | 1.955 |
| 01:58 ET | 600 | 1.955 |
| 02:00 ET | 300 | 1.955 |
| 02:02 ET | 300 | 1.955 |
Nov 8, 2024
DJ ADC Therapeutics Initiated at Overweight by Stephens & Co., from 7:18AM ET on Friday Nov 08, 2024 by Dow Jones
7:18AM ET on Friday Nov 08, 2024 by Dow Jones
Nov 7, 2024
ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update, from 7:30AM ET on Thursday Nov 07, 2024 by Dow Jones
7:30AM ET on Thursday Nov 07, 2024 by Dow JonesPress Release: ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update, from 7:30AM ET on Thursday Nov 07, 2024 by Dow Jones
7:30AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 5, 2024
ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting, from 9:48AM ET on Tuesday Nov 05, 2024 by Dow Jones
9:48AM ET on Tuesday Nov 05, 2024 by Dow Jones
Nov 4, 2024
ADC Therapeutics to Present at November Investor Conferences, from 7:15AM ET on Monday Nov 04, 2024 by Dow Jones
7:15AM ET on Monday Nov 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
ADC Therapeutics SA | 187.6M | -0.8x | --- |
Editas Medicine Inc | 195.6M | -1.0x | --- |
Enanta Pharmaceuticals Inc | 197.3M | -1.7x | --- |
Personalis Inc | 238.8M | -2.1x | --- |
MacroGenics Inc | 201.5M | -2.1x | --- |
Adaptimmune Therapeutics PLC | 162.8M | -3.0x | --- |
Company Information
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
Contact Information
- Headquarters
- Biopole, route de la Corniche 3BEPALINGES, Switzerland 1066
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Chairman of the Board
- Ron Squarer
- Chief Executive Officer, Director
- Ameet Mallik
- Chief Financial Officer
- Jose Carmona
- Chief Scientific Officer
- Patrick Van Berkel
- Chief Legal Officer
- Peter Graham
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $187.6M |
|---|---|
Revenue (TTM) | $70.7M |
Shares Outstanding | 96.7M |
ADC Therapeutics SA does not pay a dividend. | |
Beta | 1.52 |
EPS | $-2.40 |
Book Value | $-1.80 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | 2.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -195.42% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
